These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1808348)

  • 1. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
    Kanagawa S; Yosikawa Y; Dohi Y
    Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
    [No Abstract]   [Full Text] [Related]  

  • 2. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 3. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk factors in aluminum toxicity in children with chronic renal failure.
    Santos F; Massie MD; Chan JC
    Nephron; 1986; 42(3):189-95. PubMed ID: 3511396
    [No Abstract]   [Full Text] [Related]  

  • 5. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone turnover and 1,25-dihydroxycholecalciferol during treatment with phosphate binders.
    Turner C; Compston J; Mak RH; Vedi S; Mellish RW; Haycock GB; Chantler C
    Kidney Int; 1988 May; 33(5):989-95. PubMed ID: 3392888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
    Malluche HH; Monier-Faugere MC
    Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal osteodystrophy.
    Beale MG; Salcedo JR; Ellis D; Rao DD
    Pediatr Clin North Am; 1976 Nov; 23(4):873-84. PubMed ID: 186748
    [No Abstract]   [Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone disease in chronic renal failure and its modern therapy].
    Dusilová Sulková S
    Vnitr Lek; 2011; 57(7-8):620-5. PubMed ID: 21877595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus.
    Barsotti G; Lazzeri M; Polloni A; Morelli E; Giovannetti E; Lupetti S; Cupisti A; Dani L; Giovannetti S
    Adv Exp Med Biol; 1986; 208():493-9. PubMed ID: 3565160
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal osteodystrophy: past and future.
    Slatopolsky E; Lopez-Hilker S; Dusso A; Brown A; Delmez J; Martin K
    Contrib Nephrol; 1990; 78():38-45; discussion 45-6. PubMed ID: 2225842
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients].
    Fournier A; Tunchot S; Bedrossians J; Idatte JM; Bordier P
    Sem Hop; 1974 Nov; 50(45):2803-10. PubMed ID: 4375854
    [No Abstract]   [Full Text] [Related]  

  • 14. The radiographic spectrum of renal osteodystrophy.
    Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL
    Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
    Madsen S
    Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
    [No Abstract]   [Full Text] [Related]  

  • 16. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today?
    Melamed ML; Buttar RS; Coco M
    Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Opinionnaire survey on the treatment of renal osteodystrophy in Japan].
    Morii H
    Nihon Jinzo Gakkai Shi; 1983 Apr; 25(4):439-47. PubMed ID: 6620696
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
    Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
    Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
    [No Abstract]   [Full Text] [Related]  

  • 19. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.
    Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C
    Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of vitamin D therapy on renal osteodystrophy in children (author's transl)].
    Bulla M; Stock GJ; Delling G; Hofmann H; Offermann G
    Klin Wochenschr; 1980 Mar; 58(5):237-47. PubMed ID: 6249957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.